Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 6/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.41 |
| ▸ | HTR2A | P28223 | 3/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.36 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4098650 | 1.00 | IDO1 (0.46) | IDO1SLC6A4HTR2AHTR2CHTR2B | |
| SCHEMBL4098668 | 0.83 | IDO1 (0.49) | IDO1SLC6A4HTR2AHTR2CHTR2B | |
| SCHEMBL4098666 | 0.83 | IDO1 (0.49) | IDO1SLC6A4HTR2AHTR2CHTR2B | |
| SCHEMBL4098657 | 0.80 | SLC6A4 (0.46) | IDO1SLC6A4HTR2ADRD2HTR1A | |
| SCHEMBL4098655 | 0.80 | SLC6A4 (0.46) | IDO1SLC6A4HTR2ADRD2HTR1A | |
| SCHEMBL4103234 | 0.77 | HTR2A (0.50) | IDO1SLC6A4HTR2AHTR2CHTR2B | |
| SCHEMBL4103233 | 0.77 | HTR2A (0.50) | IDO1SLC6A4HTR2AHTR2CHTR2B | |
| SCHEMBL4100328 | 0.76 | HTR2A (0.54) | IDO1SLC6A4HTR2AHTR2CHTR2B | |
| SCHEMBL4100325 | 0.76 | HTR2A (0.54) | IDO1SLC6A4HTR2AHTR2CHTR2B | |
| SCHEMBL4105875 | 0.75 | AR (0.41) | SLC6A4HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7618967-B2 | Indane compounds | H. LUNDBECK A/S (DK) | 2009-11-17 | — | — | US | disclosed |
| WO-2009106559-A1 | USES OF INDANE COMPOUNDS | H. LUNDBECK A/S (DK) | 2009-09-03 | — | — | WO | disclosed |
| US-20090215774-A1 | USES OF INDANE COMPOUNDS | H. LUNDBECK A/S (DK) | 2009-08-27 | — | — | US | disclosed |
| US-20080058329-A1 | NOVEL INDANE COMPOUNDS | H. LUNDBECK A/S (DK) | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058329-A1 | NOVEL INDANE COMPOUNDS | OPRL1, HTR2C, SLC6A3 | IDO1 11/4885SLC6A4 5/4885HTR2A 15/4885 |
| US-20090215774-A1 | USES OF INDANE COMPOUNDS | GPR119, INSR, IRS1 | IDO1 19/4885SLC6A4 215/4885HTR2A 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.